Top Back to top

A prospective study on the use of Brentuximab Vedotin or Checkpoint inhibitors as bridge to autologous stem cell transplantation in Hodgkin lymphoma

Lymphoma Working Party (LWP)
Study number:
2021-N-02
Diseases:
 
Short title:
 
Primary objective:
 
Key inclusion criteria:
 
Country:
 
Principal investigator:
Ali Bazarbachi
EBMT Study coordinator:
Irma Khvedelidze
Study coordinator email:
irma.khvedelidze@upmc.fr